• Cullinan Therapeutics will host an in-person Immunology Day for analysts and institutional investors on June 10, 2026, at 8:30 a.m. ET in New York.
• Event will highlight initial clinical data from more than 30 patients in systemic lupus erythematosus, rheumatoid arthritis studies of CLN-978.
• Program also includes initial multi-dose cohort data for velinotamig in treatment-refractory autoimmune diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cullinan Therapeutics Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.